Records show that drug companies gave nearly $75,000 to the top Republican and Democrat on a committee investigating them.

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday. The ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

In a meeting on Monday, Merck Sharp & Dohme LLC proposed a substantial $900 million biologics manufacturing facility in ...

Merck & Co. and Glenmark Pharmaceuticals Ltd. failed to convince a federal judge to toss antitrust claims tied to an alleged ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Relatedly, in that HPV litigation, the first jury trial began a month ago in a California court. The plaintiff alleges that ...

Eikon is building a high-profile line of potential drugs. Its portfolio is led by EIK-1001, which is just rolling out a ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...